Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/10/20
End: 10/01/22
Due: 10/01/23
Phase: N/A
Priority: Normal
Start: 02/01/21
End: 10/01/22
Due: 10/01/23
Phase: N/A
Priority: Normal
Start: 12/19/23
End: 05/31/25
Due: 05/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema | NCT04697758 | AsclepiX Therapeutics, Inc. | user2@example.com | None | 2020-12-10 | 2022-10-01 | 2023-10-01 | - | - | 2025-07-14 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration | NCT04746963 | AsclepiX Therapeutics, Inc. | user2@example.com | None | 2021-02-01 | 2022-10-01 | 2023-10-01 | - | - | 2025-07-14 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) | NCT05859776 | AsclepiX Therapeutics, Inc. | user2@example.com | None | 2023-12-19 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |